<DOC>
	<DOCNO>NCT00116922</DOCNO>
	<brief_summary>It well establish 21st century characterize global epidemic Type 2 diabetes . The principal aim CANOE study determine whether individual pre-diabetes condition impair glucose tolerance prevent progress diabetes healthy living lifestyle intervention insulin sensitize medication . Individuals impair glucose tolerance ( IGT ) determine oral glucose tolerance test eligible participate study . All participant receive lifestyle dietary exercise intervention program . Half participant randomly assign insulin sensitize medication ( rosiglitazone/metformin ) commonly use treat Type 2 diabetes . The primary outcome study development diabetes . The study expect last total five year .</brief_summary>
	<brief_title>A Lifestyle Combination Medication Therapy Diabetes Prevention Study</brief_title>
	<detailed_description>The CANOE Study CAnadian Normoglycemia Outcomes Evaluation Study It well accept 21st Century characterize global epidemic Type 2 diabetes mellitus [ Type 2DM ] . To deal major health crisis , several strategy propose . These include effort focus primary prevention diabetes , attempt implement effective management diabetes develops , institution appropriate proven therapy establish diabetic complication . The CANOE study focus primary prevention strategy . The study design evaluate effect pharmacological therapy combine healthy living lifestyle intervention Canadian individual high risk metabolic condition IGT . OBJECTIVES - To determine treatment Avandamet , addition healthy living lifestyle program , prevent development Type 2 diabetes Canadians high risk metabolic disorder ; - To determine treatment Avandamet , addition healthy living lifestyle program improve cardiovascular risk factor associate IGT . STUDY DESIGN CANOE moderately size , randomize , double-blind control trial determine Avandamet decrease development diabetes individual high risk condition . A total 200 patient follow average follow 4 year ( range 3 - 5 year ) . Active treatment Avandamet ( Metformin 500 mg / Rosiglitazone 2 mg ) administer one capsule twice daily compare match placebo . All study participant receive lifestyle intervention program base late national evidence-based guideline recommend Canadian Diabetes Association ( Can J Diabetes , Vol 27 Suppl 2 , 2003 ) .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Residents Ontario Age 1875 IGT OGTT Current use Metformin Rosiglitazone Prior use medication treat diabetes except gestational diabetes Use drug know exacerbate glucose tolerance History diabetes except gestational diabetes Liver function study great 2.5x normal Creatinine clearance le 60 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Prevention .</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Metformin</keyword>
	<keyword>Lifestyle</keyword>
	<keyword>Impaired glucose Tolerance</keyword>
</DOC>